Introduction: The impact of the dose and fractionation of thoracic radiotherapy on the risk of developing brain metastasis (BM) has not been evaluated prospectively in limited stage SCLC patients receiving prophylactic cerebral irradiation (PCI).
Introduction
SCLC is characterized by a rapid doubling time and brain metastases (BM) are frequent in its natural history. Prophylactic cranial irradiation (PCI) in limited-stage (LS) SCLC patients has been shown to reduce the incidence of BM. Furthermore, in good performance status LS-SCLC patients who respond to standard platinumbased chemoradiotherapy (CTRT), two meta-analyses have shown that PCI led to an absolute overall survival (OS) benefit.
1,2 Therefore, PCI is considered to be part of the standard management in this setting. 3, 4 However, there are a number of unresolved issues regarding PCI. Firstly, the meta-analyses included studies that were performed before brain magnetic resonance imaging (MRI) became a standard investigation for SCLC. 3, 4 Therefore, the role of PCI in patients screened with brain MRI is uncertain. Secondly, the optimal timing of PCI delivery after CTRT is undefined, even if a trend in favor of early PCI is suggested. Finally, the impact of the dose and fractionation of thoracic radiotherapy (RT) on the risk of developing BM has not been evaluated prospectively. Accelerated hyperfractionated RT can theoretically reduce the risk of tumor cell repopulation during treatment by shortening the overall treatment time. 5 
Patients and Methods
We report here on PCI delivery and timing relating to CTRT, survival, and impact of thoracic dose fractionation on risk of brain relapse in patients treated as part of the CONVERT trial (NCT00433563). 6 CONVERT is a multicenter phase III trial that randomly assigned (1:1 using minimization method) patients with Eastern Cooperative Oncology Group performance score (PS) 0-2 with LS-SCLC to receive either twice-daily (BD; 45 Gy in 30 fractions) or once-daily (OD; 66 Gy in 33 fractions) RT starting with cycle 2 of chemotherapy. Chemotherapy consisted of 4 to 6 cycles of cisplatin and etoposide. A computed tomographic (CT) scan or MRI of the brain was mandated and preformed within 4 weeks before randomization. In this trial, patients without evidence of progressive disease after chemotherapy and with no clinical evidence of BM were offered PCI. The dose and fractionation of PCI was left to the discretion of each principal investigator to allow for variation in local practice. The trial protocol specified that PCI should start no later than 6 weeks after the last cycle of chemotherapy.
In this analysis, data on PCI status from CONVERT participants was evaluated. Descriptive statistics for the patients included in this analysis were reported. Brain relapse times and OS, for assessment of predictors were calculated from PCI initiation to time of first relapse or death, respectively. Patients who did not experience an event were right-censored. Predictors for brain relapse rates were assessed using the competing risk regression model developed by Fine and Gray, 7 whereas predictors for OS were assessed using the Cox proportional hazards model. The proportionality assumption was assessed using Schoenfeld residual plots. All analyses were conducted using R v3.4.
Results
Between April 2008 and November 2013, 547 patients from 73 centers across eight countries were recruited. Two hundred seventy-four patients were randomly assigned to receive BD CTRT and 273 to receive OD CTRT. The modified intention-to-treat survival analysis included 543 patients (273 in the BD group and 270 in the OD group); 4 patients were lost to follow-up. Baseline imaging of the brain consisted of CT scan for 356 of 449 patients (79%) and MRI for 83 of 449 (18%) patients. Of 543 patients, 449 (83%) received PCI after completion of CTRT. PCI was delivered to 220 (81%) of 273 participants in the BD group and 229 (85%) of 270 in the OD group (p ¼ 0.49). Supplementary Table 1 shows the patients characteristics according to PCI delivery. Both groups were comparable at baseline, except that no-PCI patients were older (p ¼ 0.01), and the proportion of Asian patients (p ¼ 0.01) and baseline lactic acid dehydrogenase levels were higher (p ¼ 0.04). The Union for International Cancer Control/American Joint Committee on Cancer stages of patients who received PCI were I, II, and III for 4 (1%), 74 (16%), 346 (77%), respectively, and was unknown in 25 patients.
The total median PCI dose was 25 Gy in both BD (range, 12.5-37.5 Gy) and OD (range, 2.5-30 Gy) groups (p ¼ 0.74) ( Table 2) .
The median OS in the PCI group was 29 months (95% CI: 25.8-35.7 months). Median OS was 28 months in the BD group (95% CI: 22-35) and 31 months in the OD group (95% CI: 27-52 months; p ¼ 0.1). In patients receiving PCI, the 3-year OS rates were 45% (95% CI: 40-50) 42% (95% CI: 36-49), and 48% (95% CI: 41-55) for the whole population, OD group, and BD group, respectively. In the univariate analysis of OS, PCI timing from end of chemotherapy, weight loss of more than 10%, and tGTV were prognostic factors. In the multivariate analysis, only tGTV was associated with OS. PCI timing from end of chemotherapy did not remain significantly associated with OS (p ¼ 0.2) ( Table 2 ). The median OS in the non-PCI group was 11.8 (95% CI: 8.7-17.6) months. Excluding patients with poor prognosis who had either unknown or progressive disease after CTRT, the median OS in the non-PCI group was 13.9 months (95% CI: 9.5-24.8 months, p < 0.001 versus the PCI group).
Discussion
The role of PCI in the management of LS-SCLC has been controversial due to the potential risk of neuropsychological toxicity. 1, 8 The recently published Japanese trial comparing active brain MRI surveillance to PCI in extensive-stage SCLC has challenged the standard of care established by the European Organisation for Research and Treatment of Cancer (EORTC) trial in 2007. 9, 10 In the Japanese trial, PCI did not result in longer OS compared with observation (median 11.6 months versus 13.7 months; p ¼ 0.09). The latter trial has been scrutinized given that some cofactors might have attenuated the benefits of PCI (e.g., important rates of salvage brain RT with probable salvage radiosurgery N, total number of patients; BP, number of patients with brain progression; OP, number of patients with other radiological progressions; tGTV, thoracic gross tumor volume; OD, once-daily; BD, twice-daily; HR, hazard ratio; CI, confidence interval; CTRT, chemoradiotherapy; MRI, magnetic resonance imaging; ECOG PS, Eastern Cooperative Oncology Group performance score; PCI, prophylactic cranial irradiation.
in both groups). 11, 12 Consequently, there is a clear need for new PCI trials performed in the MRI era. In LS-SCLC, a recent U.S. survey of practice showed that most (n ¼ 309) radiation oncologists recommend PCI (98%) and brain MRI before treatment (96%). 13 There is also a need to develop decision support systems to guide doctors and patients. In the CONVERT trial, we showed that larger tumors, but not the thoracic fractionation type, are associated with a higher risk of BM, but also higher risk of extracranial recurrences.
14 Predictive models must be refined to achieve more personalized management.
